FindTrial
Sign In

Radionuclide treatment in pheochromocytoma

Radionuclide therapy in Pheochromocytoma/ paraganglioma (PPGL): A retrospective single centre study.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/05/019349
Enrollment
100
Registered
2019-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C7A8- Other malignant neuroendocrine tumors

Interventions

Intervention1: nil: nil

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient with metastatic (synchronous/metachronous) or inoperable Pheochromocytoma and Paraganglioma who have received radionuclide therapy either MIBG or PRRT with minimum 3 months of follow up.

Exclusion criteria

Exclusion criteria: Patients of PPGL who have not received radionuclide therapy

Design outcomes

Primary

MeasureTime frame
Response to treatmentTimepoint: 6 months—

Secondary

MeasureTime frame
nilTimepoint: not applicable—

Countries

India

Contacts

Public ContactDr Tushar Bandgar

KEM Hospital

drtusharb@gmail.com9820025037

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026